Status:
COMPLETED
Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects
Lead Sponsor:
Bellus Health Inc. - a GSK company
Conditions:
Healthy
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
This is a Phase I, Double-Blind, Randomised, Adaptive-designed Study to Assess the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects Following Single and Multipl...
Eligibility Criteria
Inclusion
- Healthy males or non-pregnant, non-lactating healthy females
Exclusion
- History of neurological, endocrine, cardiovascular, respiratory, haematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease.
Key Trial Info
Start Date :
August 6 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 21 2021
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT06179537
Start Date
August 6 2021
End Date
November 21 2021
Last Update
December 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Richmond Pharmacology Ltd.
London, United Kingdom, SE1 1YR